Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051558 | 0.83 | BRD4 (0.57) | PTGER1SGMS2KMT2ABRD4 | |
| Pyridine SCHEMBL28554937 | 0.78 | BRD4 (0.52) | PTGER1SGMS2KMT2ABRD4 | |
| SCHEMBL1116613 | 0.77 | GCGR (0.40) | PTGER1KMT2AKDM5AKDM2BKDM4C | |
| SCHEMBL21434681 | 0.77 | BRD4 (0.51) | PTGER1SLC6A4SGMS2KMT2APLAU | |
| SCHEMBL1425671 | 0.75 | PTGER1 (0.47) | PTGER1SLC6A4SGMS2KMT2ABRD4 | |
| SCHEMBL11357103 | 0.75 | PTGER1 (0.51) | PTGER1SLC6A4HTR2CHTR2B | |
| SCHEMBL2092181 | 0.74 | BRD4 (0.41) | SGMS2LRRK2BRD4 | |
| SCHEMBL1107053 | 0.73 | PTGDR (0.46) | KMT2A | |
| SCHEMBL31517973 | 0.73 | SMN1; SMN2 (0.44) | SGMS2LRRK2PLAUBRD4 | |
| SCHEMBL12002483 | 0.73 | LRRK2 (0.38) | PTGER1SGMS2LRRK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | PTGER1 7/4885SLC6A4 1329/4885SGMS2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.